MedTrace Logo

Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)

NCT05717803 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 307

Last updated 2024-06-03

No results posted yet for this study

Summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1012. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are:

* The 5-year disease-free survival of patients having ground glass-dominant invasive lung cancer with size of 2-3cm;
* The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.

Conditions

Interventions

PROCEDURE

Segmentectomy

The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Haiquan Chen, M.D. · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2028-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05717803 on ClinicalTrials.gov